NCT01090245

Brief Summary

Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment program to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months. Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment. Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment. Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling. Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
202

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2010

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 19, 2010

Completed
13 days until next milestone

Study Start

First participant enrolled

April 1, 2010

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
Last Updated

May 10, 2017

Status Verified

May 1, 2017

Enrollment Period

3.8 years

First QC Date

March 16, 2010

Last Update Submit

May 9, 2017

Conditions

Keywords

contingency managementsubstance abuse treatmentcriminal justice populationssubstance abuse treatment retentionHIV prevention in criminal justice settingsvoucher based reinforcement therapyParole treatment admission for substance abusing paroleesParole treatment retention for substance abusing paroleesHIV testing and counseling for substance abusing parolees

Outcome Measures

Primary Outcomes (3)

  • Community treatment admission

    Within 7 days of release to parole

  • Community treatment retention

    6 months

  • Participation in HIV testing and counseling

    2 months

Secondary Outcomes (3)

  • Substance abuse

    18 months after release from prison

  • Arrest and reincarceration

    18 months after release from prison

  • psychosocial: employment, education, family relationships, psychological functioning, and HIV risk

    18 months after release from prison

Study Arms (2)

Attendance Information Group

ACTIVE COMPARATOR

Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.

Behavioral: Information

Attendance Incentive Group

EXPERIMENTAL

Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.

Behavioral: Contingency management: voucher/monetary incentives for treatment attendance

Interventions

Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.

Attendance Incentive Group
InformationBEHAVIORAL

Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.

Attendance Information Group

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 18 years of age
  • English speaking
  • Within one month of parole
  • Able to provide informed consent to participate in the study
  • Received a referral to the Walden House Los Angeles Transitional Treatment Center

You may not qualify if:

  • Potential subjects will be excluded from participating if they have serious cognitive problems that preclude their ability to provide informed consent or understanding of the questionnaire items, if they are a sexually violent predator or a child molester or if they have severe mental health problems.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Saxena P, Hall EA, Prendergast M. A Randomized Study of Incentivizing HIV Testing for Parolees in Community Aftercare. AIDS Educ Prev. 2016 Apr;28(2):117-27. doi: 10.1521/aeap.2016.28.2.117.

MeSH Terms

Conditions

Substance-Related DisordersHIV Infections

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersMental DisordersBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Michael L Prendergast, Ph.D.

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR
  • Elizabeth A Hall, Ph.D.

    University of California, Los Angeles

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Historian

Study Record Dates

First Submitted

March 16, 2010

First Posted

March 19, 2010

Study Start

April 1, 2010

Primary Completion

January 1, 2014

Study Completion

August 1, 2014

Last Updated

May 10, 2017

Record last verified: 2017-05